Program
GT719
A development code. Also written as “GT719 Injection”.
Its studies are mostly in Hematologic Neoplasms · Autoimmune Diseases, led by Grit Biotechnology.
Furthest: phase 2, since Apr 22, 20255 company-led studies, 5 open or runningNext primary completion: Dec 1, 2027 (early phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Grit Biotechnology | 55 open or running | phase 2since Apr 22, 2025 | Apr 22, 2025 | Dec 1, 2027early phase 1 · NCT07131254 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 22, 2025First study: phase 2 study in Hematologic NeoplasmsFirst studyNCT06948981 · 46 planned · China
- May 29, 2025Phase 1 study in Neurological Autoimmune DiseasesNCT07021209 · 30 planned · China
- Jun 26, 2025Early phase 1 study in Hematologic NeoplasmsNCT07131254 · 34 planned · China
- Jul 29, 2025Early phase 1 study in Autoimmune DiseasesNCT07122076 · 10 planned · China
- Aug 14, 2025Early phase 1 study in Auto Immune DiseaseNCT07132112 · 30 planned · China
Ahead
- Dec 1, 2027Primary completion: early phase 1 study in Hematologic NeoplasmsNCT07131254
- Jan 13, 2028Primary completion: phase 1 study in Neurological Autoimmune DiseasesNCT07021209
- Apr 17, 2028Primary completion: phase 2 study in Hematologic NeoplasmsNCT06948981
- Aug 2028Primary completion: early phase 1 study in Auto Immune DiseaseNCT07132112
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07132112Auto Immune Disease · China | Early 1 | Recruiting | Aug 2028 | 30 |
| NCT07122076Autoimmune Diseases · China | Early 1 | Recruiting | Aug 21, 2028 | 10 |
| NCT07131254Hematologic Neoplasms · China | Early 1 | Recruiting | Dec 1, 2027 | 34 |
| NCT07021209Neurological Autoimmune Diseases · China | 1 | Recruiting | Jan 13, 2028 | 30 |
| NCT06948981Hematologic Neoplasms · China | 2 | Recruiting | Apr 17, 2028 | 46 |
How it is read
Names in the registry
- “GT719 Injection”, 5 entries
Codes read as this program: GT719.
Conditions, from the studies’ own filings
- Hematologic Neoplasms, 2 studies
- Autoimmune Diseases, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.